Versant Venture Capital VI, L.P.'s Form 4 filing
LAVA Therapeutics NV (LVTX) · filed Sep 18, 2025
- Accession no.
- 0001193125-25-207677
- Filed
- Sep 18, 2025, 6:49 PM ET
- Trade date
- Sep 16-18, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions. Open-market sales total $2.50M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Versant Venture Capital VI, L.P.CIK 0001687880 | 10% Owner |
| Versant Vantage I, L.P.CIK 0001765253 | 10% Owner |
| Versant Vantage I GP, L.P.CIK 0001777651 | 10% Owner |
| Versant Ventures VI GP-GP, LLCCIK 0001777652 | 10% Owner |
| Versant Vantage I GP-GP, LLCCIK 0001777653 | 10% Owner |
| Versant Ventures VI GP, L.P.CIK 0001777654 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2025 | Common Stock | SSaleDisposed | −307,707 | $1.53F1 | −$471,776.37 | 3,099,450 | Direct | |
| Sep 16, 2025 | Common Stock | SSaleDisposed | −192,293 | $1.53F1 | −$294,823.63 | 988,387 | Indirect | |
| Sep 17, 2025 | Common Stock | SSaleDisposed | −362,806 | $1.49F4 | −$540,290.7 | 2,736,644 | Direct | |
| Sep 17, 2025 | Common Stock | SSaleDisposed | −226,726 | $1.49F4 | −$337,640.36 | 761,661 | Indirect | |
| Sep 18, 2025 | Common Stock | SSaleDisposed | −366,111 | $1.44F5 | −$527,858.84 | 2,370,533 | Direct | |
| Sep 18, 2025 | Common Stock | SSaleDisposed | −228,791 | $1.44F5 | −$329,870.86 | 532,870 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.50 to $1.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.47 to $1.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Referenced by the price of 2 transactions in Table I.
- F5
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.43 to $1.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
Referenced by the price of 2 transactions in Table I.